血浆代谢组学特征与晚期及致死性前列腺癌风险
在癌症预防研究-II营养队列的病例-队列研究中,对14210名无癌男性的血浆样本进行非靶向质谱代谢组学检测,分析699种已知代谢物与晚期及致死性前列腺癌的关联。发现6种代谢物与致死性前列腺癌显著相关,基于4种代谢物的代谢风险评分与致死性前列腺癌强烈相关(每标准差相对风险2.72,95%CI 2.05-3.60),但无代谢物与晚期前列腺癌显著相关。
要点
- 6种代谢物(乙基丙二酸、丁酰肉碱、天冬氨酸、鞘磷脂(d18:1/18:0)、γ-谷氨酰甲硫氨酸、γ-谷氨酰谷氨酰胺)与致死性前列腺癌显著相关(错误发现率<0.2)。
- γ-谷氨酰氨基酸每升高1个标准差与风险降低34-38%相关,其余代谢物每升高1个标准差与风险增加45-53%相关。
- 基于4种代谢物的代谢风险评分与致死性前列腺癌强烈相关,每标准差相对风险2.72(95%CI 2.05-3.60)。
核心结论
- 这些发现识别了致死性前列腺癌发生过程中发生改变的代谢通路。
- 作者认为进一步研究这些通路可能为致死性前列腺癌的病因学提供见解。
研究设计与样本
- 癌症预防研究-II营养队列的病例-队列研究,纳入14210名无癌男性,1998-2001年采集血样。
- 截至2013年6月,129例诊断为晚期前列腺癌(T3-T4或N1或M1);截至2014年12月,112例死于前列腺癌。
- 随机选取347名男性组成子队列,使用非靶向质谱平台进行代谢组学检测。
- 采用Prentice加权Cox比例风险回归模型评估699种已知代谢物与晚期及致死性前列腺癌的关联。
主要发现
- 6种代谢物与致死性前列腺癌显著相关(错误发现率<0.2):乙基丙二酸、丁酰肉碱、天冬氨酸、鞘磷脂(d18:1/18:0)、γ-谷氨酰甲硫氨酸、γ-谷氨酰谷氨酰胺。
- γ-谷氨酰氨基酸每升高1个标准差与风险降低34-38%相关,其余代谢物每升高1个标准差与风险增加45-53%相关。
- 基于4种代谢物(排除丁酰肉碱和γ-谷氨酰谷氨酰胺,二者非独立预测因子)的代谢风险评分与致死性前列腺癌强烈相关,每标准差相对风险2.72(95%CI 2.05-3.60)。
- 无代谢物与晚期前列腺癌显著相关。
局限性
- 结果为观察性研究,可能不具因果性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the underlying molecular mechanisms of prostate cancer, especially advanced and fatal prostate cancer. OBJECTIVE: To examine associations of prediagnostic plasma metabolomic profiles with advanced and fatal prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: In a case-cohort study of the Cancer Prevention Study-II Nutrition Cohort, of 14 210 cancer-free men with a blood sample in 1998-2001, 129 were diagnosed with advanced prostate cancer (T3-T4 or N1 or M1) through June 2013 and 112 died from prostate cancer through December 2014. Plasma samples from advanced and fatal cases, and a randomly selected subcohort of 347 men were metabolically profiled using untargeted mass spectroscopy-based platforms. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prentice-weighted Cox proportional hazards regression models were used to assess associations of 699 known metabolites with advanced and fatal prostate cancer. RESULTS AND LIMITATIONS: Two metabolites derived from fatty acid metabolism (ethylmalonate and butyrylcarnitine), aspartate, sphingomyelin (d18:1/18:0), and two γ-glutamyl amino acids (γ-glutamylmethionine and γ-glutamylglutamine) were statistically significantly associated (false discovery rate <0.2) with fatal prostate cancer. One standard deviation (SD) increase in each γ-glutamyl amino acid was associated with 34-38% decreased risk, whereas one SD increase in each of the other metabolites was associated with 45-53% increased risk. A metabolic risk score based on four of these metabolites (excluding butyrylcarnitine and γ-glutamylglutamine, which were not independent predictors) was strongly associated with fatal prostate cancer (relative risk per SD: 2.72, 95% confidence interval: 2.05-3.60). No metabolites were statistically significantly associated with advanced prostate cancer. These results were observational and may not be causal. CONCLUSIONS: These findings identified metabolic pathways that are altered in the development of fatal prostate cancer. Further research into these pathways may provide insights into the etiology of fatal prostate cancer. PATIENT SUMMARY: In a large follow-up study of cancer-free men, those with a certain metabolomic profile had a higher risk of dying from prostate cancer.
引用
- Wang Y, Jacobs EJ, Carter BD, et al. Plasma Metabolomic Profiles and Risk of Advanced and Fatal Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31378665. doi:10.1016/j.euo.2019.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。